Free Research Reports on ARNA, GPOR, SWHC and VNDA Issued by the Bedford Report
19 12월 2012 - 10:15PM
Marketwired
The Bedford Report has released new equity reports today. As a
leading provider of free in depth reports and timely market
updates, Bedford is an essential resource for hundreds of thousands
of investors across the country.
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)
shares of the anti-obesity drug maker have gained over 400 percent
year-to-date. The company last month entered into a co-development
and license agreement with Ildong Pharmaceutical Co., Ltd., for
temanogrel, a novel agent for thrombotic diseases.
Find out more about Arena Pharmaceuticals
including full access to the free equity report at:
www.BedfordReport.com/ARNA
Gulfport Energy Corporation (NASDAQ: GPOR)
shares of the oil & gas company have gained over 33 percent
year-to-date. The company has recently entered into a definitive
agreement to purchase approximately 30,000 net acres in the Utica
Shale.
Find out more about Gulfport Energy
including full access to the free equity report at:
www.BedfordReport.com/GPOR
Smith & Wesson Holding Corp. (NASDAQ:
SWHC) shares of the gun maker fell 10 percent on more than 22
million shares traded Tuesday. Pressure to tighten the nation's gun
laws has increased following the shooting at Sandy Hook elementary
school in Connecticut.
Find out more about Smith & Wesson
including full access to the free equity report at:
www.BedfordReport.com/SWHC
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)
shares soared nearly 20 percent on over 4.5 million shares traded
Tuesday after reporting positive results from a Phase III study of
tasimelteon, a circadian regulator for the treatment of Non-24-Hour
Disorder.
Find out more about Vanda Pharmaceuticals
including full access to the free equity report at:
www.BedfordReport.com/VNDA
Disclaimer: Information, opinions and analysis contained herein
are based on sources believed to be reliable, but no
representation, expressed or implied, is made as to its accuracy,
completeness or correctness. The opinions contained herein reflect
our current judgment and are subject to change without notice. We
accept no liability for any losses arising from an investor's
reliance on or use of this report. This report is for information
purposes only, and is neither a solicitation to buy nor an offer to
sell securities. Certain information included herein is
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements concerning manufacturing, marketing, growth, and
expansion. Such forward-looking information involves important
risks and uncertainties that could affect actual results and cause
them to differ materially from expectations expressed herein.
A third party, Providence Media Strategies LLC has paid Equity
News Circuit four hundred and fifty dollars for the publication of
this news release. Neither Equity News Circuit, nor the hiring
party, has a financial relationship with any company whose stock is
mentioned in this release. Neither Equity News Circuit nor the
hiring party are a registered investment advisor, and nothing in
this report is intended as a solicitation to buy or sell any
security.
Contact Information: Equity News Circuit Email Contact
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024